鍏充簬骞叉€э紙闈炴笚鍑烘€э級骞撮緞鐩稿叧鎬ч粍鏂戝彉鎬�<\/b><\/p> \n

骞撮緞鐩稿叧鎬ч粍鏂戝彉鎬э紙AMD锛夋槸涓€绉嶇溂閮ㄩ€€琛屾€х柧鐥咃紝鐩墠褰卞搷鐫€鍏ㄧ悆鏁扮櫨涓囦汉锛�<\/span>鏄€佸勾浜虹兢涓鑷村け鏄庣殑涓昏鍘熷洜銆備复搴婁笂骞叉€MD鎮ｈ€呯害鍗燗MD鎬绘暟鐨�80-90%銆傛埅鑷� 2020 骞达紝涓浗骞叉€� AMD 鎮ｈ€呬汉鏁扮害涓� 3350 涓囷紝棰勮鍒�2030骞存湯灏嗚秴杩� 4300 涓�^{1<\/sup>銆傜洰鍓嶏紝瀵逛簬骞叉€MD鎮ｈ€咃紝浠嶅皻鏃犲凡鑾锋壒鐨勬湁鏁堟不鐤楁柟娉曘€�<\/p> \n}

2015骞达紝闊╃編鍒惰嵂浠� Allegro Ophthalmic LLC 鑾峰緱浜� Risuteganib (Luminate^{®<\/sup>) 鍦ㄩ煩鍥藉拰涓浗杩涜鐜荤拑浣撳唴娉ㄥ皠鐨勭嫭瀹跺紑鍙戝拰鍟嗕笟鍖栨潈鍒┿€侺uminate^{®<\/sup> 鏄� Integrin 璋冭妭鍓傚悓绫讳骇鍝佷腑鐨勯鍒涙柊鑽紝鍏跺叿澶囧叏鏂扮殑浣滅敤鏈哄埗锛岃兘澶熻皟鑺傚寘鎷嚎绮掍綋鍔熻兘闅滅鍦ㄥ唴姘у寲搴旀縺鍙嶅簲鐨勫涓€氳矾锛屼粠鑰屾不鐤楃嚎绮掍綋鍔熻兘闅滅寮曞彂鐨勫共鎬� AMD 绛夌柧鐥呫€俁isuteganib (Luminate^{®<\/sup>) 鍦ㄤ竴椤瑰共鎬MD 2 鏈熶复搴婅瘯楠屼腑鎴愬姛杈惧埌涓昏鐤楁晥缁堢偣锛屼笌鍋囨敞灏勭粍鐩告瘮锛孉M011 鍙湁鏁堥€嗚浆涓湡骞叉€MD寮曡捣鐨勮鍔涗抚澶便€侫llegro 宸蹭笌缇庡浗椋熷搧鍜岃嵂鐗╃鐞嗗眬 (FDA) 杈炬垚鐗瑰埆鏂规璇勫 (Special Protocol Assessment锛孲PA) 鍗忚锛屼互鎺ㄨ繘 Risuteganib (Luminate^{®<\/sup>) 杩涘叆2b\/3 鏈熷叧閿复搴婅瘯楠屾敞鍐岃鍒掋€�<\/p> \n}}}}

钄肩潶鍖荤枟鏄竴瀹跺叏鐞冨垱鏂板尰鑽鎶€鍏徃锛岃嚧鍔涗簬寮€鍙戝拰鍟嗕笟鍖栭潻鏂版€ц嵂鐗┿€佹暟瀛楃枟娉曞拰鍖荤枟鍣ㄦ浜у搧锛屼互婊¤冻澶т腑鍗庡湴鍖哄拰鍏ㄧ悆鎮ｈ€呭湪鐪肩銆佺缁忓拰绮剧绯荤粺鐤剧梾娌荤枟棰嗗煙灏氭湭婊¤冻鐨勫叧閿尰鐤楅渶姹傘€傝敿鐫﹀尰鐤楃殑绠＄悊鍥㈤槦鎷ユ湁鍏ㄩ潰鐨勪笓涓氱煡璇嗗拰琛屼笟缁忛獙锛屽苟鍏堝悗鍦ㄤ腑鍥藉強鍏ㄧ悆棰嗗厛璺ㄥ浗鐢熺墿鍒惰嵂鍏徃鎷呬换楂樼骇绠＄悊鑱屽姟锛屾垚鍔熸帹杩涘拰涓诲鍒涙柊鑽墿鍙戠幇銆佷复搴婂紑鍙戙€佹敞鍐屼簨鍔°€佷笟鍔℃嫇灞曘€佺敓浜у埗閫犲拰鍟嗕笟杩愯惀涓氬姟銆�<\/p> \n

闊╃編鍒惰嵂鎴愮珛浜�1973骞达紝鏄竴瀹舵€婚儴浣嶄簬闊╁浗鐨勭爺鍙戝瀷鐢熺墿鍒惰嵂鍏徃銆傜敱鑽墏甯堟灄鎴愬熀鎴愮珛鍚庯紝浜�2010骞磋浆鍙樹负鎺ц偂鍏徃锛屾垚涓洪煩缇庣瀛︾殑瀛愬叕鍙搞€傞煩缇庡埗鑽瘡骞存湁瓒呰繃15%鐨勯攢鍞鎶曞叆鍒扮爺鍙戯紝鍦ㄤ笁澶ч鍩熷紑鍙�26涓垱鏂板€欓€夎嵂鐗�; 1锛夌敓鐗╁埗鑽細LAPSCOVERY 骞冲彴搴旂敤闀挎晥绠＄嚎锛�2锛塏CE锛氫富瑕佷负閽堝鑲跨槫鍜岃嚜韬厤鐤€х柧鐥呯殑绠＄嚎锛涗互鍙�3锛夊浐瀹氬墏閲忕粍鍚堥」鐩€傞煩缇庡埗鑽叿鏈変唬琛ㄦ€х殑鏂拌嵂闈跺悜鐤剧梾鍖呮嫭鑲ヨ儢銆佺綍瑙佺梾銆佸悇绫荤檶鐥囩瓑浠ｈ阿鎬х柧鐥呫€傛澶栵紝闊╃編鍒惰嵂杩樼粡钀ョ潃浠庡師鏉愭枡鍒板寲瀛﹀搧鍜岀敓鐗╁埗鑽殑鐢熶骇璁炬柦锛屽湪闊╁浗鍜屼腑鍥芥嫢鏈�5,000澶氬悕鍛樺伐銆�<\/p> \n

\n \n \n \n
1. Frost & Sullivan. January 2022. Global Market Study of CNS and Ophthalmic Treatment Market, 2022. Shanghai, China.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p>"]; $("#dvExtra").html(content_array[0]);})();